Compare HEI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HEI | ZTS |
|---|---|---|
| Founded | 1957 | 1952 |
| Country | United States | United States |
| Employees | 11100 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 48.7B |
| IPO Year | N/A | 2012 |
| Metric | HEI | ZTS |
|---|---|---|
| Price | $280.22 | $116.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $365.58 | $156.20 |
| AVG Volume (30 Days) | 726.6K | ★ 3.3M |
| Earning Date | 02-25-2026 | 05-05-2026 |
| Dividend Yield | 0.09% | ★ 1.83% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $13.98 | $5.69 |
| Revenue Next Year | $8.53 | $4.81 |
| P/E Ratio | $69.84 | ★ $19.17 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $229.07 | $114.36 |
| 52 Week High | $361.69 | $172.23 |
| Indicator | HEI | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 32.89 | 38.26 |
| Support Level | N/A | N/A |
| Resistance Level | $324.73 | $130.52 |
| Average True Range (ATR) | 8.41 | 3.34 |
| MACD | -2.17 | -0.54 |
| Stochastic Oscillator | 19.40 | 22.43 |
Heico is an aerospace and defense supplier that focuses on creating replacement parts for commercial aircraft and components for defense products. In commercial aerospace, Heico is the largest independent producer of replacement aircraft parts. In the defense market, the company produces niche subcomponents used in targeting technology as well as simulation equipment, among other categories. It operates as two segments: the flight support group and the electronic technologies group. Both supply the aerospace and defense sectors to different degrees. Heico is persistently acquisitive, focusing on companies in similar or adjacent markets that offer strong cash flow and profitable growth potential.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.